Experimental drug JS015 takes first steps against advanced solid tumors
NCT ID NCT05770310
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This early-stage trial tests an experimental drug called JS015 in people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the best dose, and see how the body processes it. Up to 12 participants will receive JS015 by intravenous infusion, with researchers monitoring side effects and any signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental drug called JS015
- What this could lead to
- If this trial shows JS015 is safe and tolerable, it could lead to larger studies testing whether it can shrink or slow advanced solid tumors.
- What could go wrong
- This is a very early, small Phase I trial focused on safety, not effectiveness. The drug may not work against tumors or could cause unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Cancer Hospital of Harbin Medical University
Harbin, Heilongjiang, 150081, China
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Shandong Cancer Hospital
Jinan, Shandong, 250117, China
-
Shanghai Oriental Hospital
Shanghai, Shanghai Municipality, 200120, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could an AI-Designed pill take on Hard-to-Treat cancers?
- Can a new nucleotide analogue boost cancer treatment?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
- Can a new antibody help the immune system fight advanced cancers?
- Can an experimental pill slow advanced solid tumors? a phase 1 trial puts HW221043 to the test.